Show simple item record

dc.contributor.authorGaibar Alonso, María
dc.contributor.authorNovillo, Apolonia
dc.contributor.authorRomero Lorca, Alicia
dc.contributor.authorMalón, Diego
dc.contributor.authorAntón, Beatriz
dc.contributor.authorMoreno, Amalia
dc.contributor.authorFernández Santader, Ana
dc.date.accessioned2022-02-23T09:21:58Z
dc.date.available2022-02-23T09:21:58Z
dc.date.issued2021
dc.identifier.issn1999-4923spa
dc.identifier.urihttp://hdl.handle.net/10641/2854
dc.language.isoengspa
dc.publisherPharmaceuticsspa
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/*
dc.subjectHER2-positive breast cancerspa
dc.subjectAnti-HER2 treatmentspa
dc.subjectFGFR1 genespa
dc.subjectPathological complete responsespa
dc.subjectMiller–Payne gradingspa
dc.titleFGFR1 Amplification and Response to Neoadjuvant Anti-HER2 Treatment in Early HER2-Positive Breast Cancer.spa
dc.typearticlespa
dc.description.versionpost-printspa
dc.rights.accessRightsopenAccessspa
dc.description.extent262 KBspa
dc.identifier.doi10.3390/pharmaceutics14020242spa
dc.relation.publisherversionhttps://www.mdpi.com/1999-4923/14/2/242spa


Files in this item

FilesSizeFormatView
1.- FGFR1 Amplification and ...261.5KbPDFView/Open

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-SinDerivadas 3.0 España
Except where otherwise noted, this item's license is described as Atribución-NoComercial-SinDerivadas 3.0 España